GRIN Therapeutics Announces First Patient Dosed in Phase 1B Clinical Trial with Radiprodil for Treatment of GRIN-related Disorders

Milestone represents initiation of first-ever clinical trial using NR2B-negative allosteric modulator to treat GRIN-related disorders March 23, 2023 07:00 AM Eastern Daylight Time NEW YORK--(BUSINESS WIRE)--GRIN Therapeutics Inc., a leader in development of therapies to treat GRIN-related disorders, today announced that the first patient has been dosed in the Honeycomb Study, the Company’s Phase 1B

Registrati on line alla conferenza GRI 2023

We are delighted to announce that virtual registration for #GRIcon2023 is now OPEN!The virtual conference is a Pay What You Can event. Our suggested ticket price is $79 per person / household, but we don't want anyone to miss out because of cost. Whatever your connection to GRI Disorder, feel free to register for free or

Torna in cima